Back to Search
Start Over
Merck passes European Commission's approval for Mavenclad for treating highly active relapsing multiple sclerosis in the EU
- Source :
- M2 EquityBites (EQB). August 25, 2017
- Publication Year :
- 2017
-
Abstract
- M2 EQUITYBITES-August 25, 2017-Merck passes European Commission's approval for Mavenclad for treating highly active relapsing multiple sclerosis in the EU (C)2017 M2 COMMUNICATIONS http://www.m2.com Science and technology company Merck reported [...]
Details
- Language :
- English
- Database :
- Gale General OneFile
- Journal :
- M2 EquityBites (EQB)
- Publication Type :
- News
- Accession number :
- edsgcl.501705484